Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Operating Leases (2019 - 2026)

Ekso Bionics Holdings has reported Operating Leases over the past 7 years, most recently at $147000.0 for Q4 2025.

  • On a quarterly basis, Operating Leases fell 67.48% to $147000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $147000.0, a 67.48% decrease, with the full-year FY2025 number at $147000.0, down 67.48% from a year prior.
  • Operating Leases reached $147000.0 in Q4 2025 per EKSO's latest filing, down from $698000.0 in the prior quarter.
  • The five-year high for Operating Leases was $1.4 million in Q3 2022, with the low at $97000.0 in Q1 2022.
  • The 5-year median for Operating Leases is $662000.0 (2024), against an average of $671166.7.
  • Peak YoY movement for Operating Leases: crashed 83.36% in 2021, then skyrocketed 1289.69% in 2023.
  • Tracing EKSO's Operating Leases over 5 years: stood at $372000.0 in 2021, then skyrocketed by 192.2% to $1.1 million in 2022, then tumbled by 33.49% to $723000.0 in 2023, then crashed by 37.48% to $452000.0 in 2024, then plummeted by 67.48% to $147000.0 in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $147000.0, $698000.0, and $358000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.